The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-05-20 DOI:10.1002/clc.24284

Michael Khorsandi MD, Roger S. Blumenthal MD, Michael J. Blaha MD, MPH, Payal Kohli MD

{"title":"The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease","authors":"Michael Khorsandi MD, Roger S. Blumenthal MD, Michael J. Blaha MD, MPH, Payal Kohli MD","doi":"10.1002/clc.24284","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The 2023 Multisociety Guideline for the Management of Chronic Coronary Disease (CCD) updates recommendations for CCD, formerly known as “stable ischemic heart disease.” This condition encompasses a spectrum of coronary vascular pathologies from subclinical to clinical ischemic heart disease.</p>\n </section>\n \n <section>\n \n <h3> Hypothesis</h3>\n \n <p>The new “ABC” mnemonic offers clinicians a streamlined framework for applying Class One Recommendations (COR1) and integrating recent updates into CCD management.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A critical analysis of the 2023 CCD guidelines was conducted, with this review highlighting key elements.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The review outlines crucial changes, including novel recommendations supported by current clinical evidence. The focus is on these developments, clarifying their importance for day-to-day clinical practice.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The review encourages a synergistic approach between primary healthcare providers and cardiologists to develop comprehensive strategies for lifestyle modification and medication therapy in CCD care. Furthermore, it suggests that utilizing comprehensive risk assessment tools can refine medical decision-making, ultimately enhancing patient care and clinical outcomes.</p>\n </section>\n </div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.24284","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.24284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The 2023 Multisociety Guideline for the Management of Chronic Coronary Disease (CCD) updates recommendations for CCD, formerly known as “stable ischemic heart disease.” This condition encompasses a spectrum of coronary vascular pathologies from subclinical to clinical ischemic heart disease.

Hypothesis

The new “ABC” mnemonic offers clinicians a streamlined framework for applying Class One Recommendations (COR1) and integrating recent updates into CCD management.

Methods

A critical analysis of the 2023 CCD guidelines was conducted, with this review highlighting key elements.

Results

The review outlines crucial changes, including novel recommendations supported by current clinical evidence. The focus is on these developments, clarifying their importance for day-to-day clinical practice.

Conclusions

The review encourages a synergistic approach between primary healthcare providers and cardiologists to develop comprehensive strategies for lifestyle modification and medication therapy in CCD care. Furthermore, it suggests that utilizing comprehensive risk assessment tools can refine medical decision-making, ultimately enhancing patient care and clinical outcomes.

Abstract Image

查看原文本刊更多论文

2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠心病患者管理指南 ABC。

背景：2023 年多协会慢性冠状动脉疾病（CCD）管理指南》更新了对 CCD（以前称为 "稳定型缺血性心脏病"）的建议。这种疾病包括从亚临床到临床缺血性心脏病的一系列冠状动脉血管病变：新的 "ABC "记忆法为临床医生应用一级建议（COR1）和将最新进展纳入 CCD 管理提供了一个简化框架：方法：对 2023 年 CCD 指南进行了批判性分析，本综述强调了其中的关键要素：结果：综述概述了关键的变化，包括有当前临床证据支持的新建议。重点是这些发展，阐明其对日常临床实践的重要性：综述鼓励初级医疗保健提供者和心脏病专家采取协同合作的方式，在 CCD 护理中制定生活方式调整和药物治疗的综合策略。此外，综述还表明，利用综合风险评估工具可以完善医疗决策，最终改善患者护理和临床效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464